Pregnancy in essential thrombocythemia during aspirin treatment.

Arch Gynecol Obstet

Dipartimento di Scienze Ginecologiche, Ostetriche e Medicina della Riproduzione, Università di Messina, Messina, Italy.

Published: August 2003

Introduction: Essential thrombocythemia is a rare disease of unknown origin characterized by abnormal increase in the platelet count.

Case Report: We report a case diagnosed in a woman who had had an early miscarriage in her first pregnancy, a voluntary abortion because a fetal chromosomal aberration in the second pregnancy and at last a third normal pregnancy. Treatment with low-dose aspirin (100 mg/day) and the use of low molecular weight heparin in the last three weeks of gestation appears to improve the obstetric outcome.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-003-0520-yDOI Listing

Publication Analysis

Top Keywords

essential thrombocythemia
8
pregnancy
4
pregnancy essential
4
thrombocythemia aspirin
4
aspirin treatment
4
treatment introduction
4
introduction essential
4
thrombocythemia rare
4
rare disease
4
disease unknown
4

Similar Publications

Essential thrombocythemia (ET) is a type of myeloproliferative neoplasm (MPN) disorder characterized by persistent thrombocytosis and characterized by frequent association with cellular genetic alterations. The 10%-15% of ET that is not associated with genetic abnormalities is known as triple-negative essential thrombocythemia (TNET). A common complication observed in around 20% of ET patients is the development of acquired von Willebrand disease (AvWD).

View Article and Find Full Text PDF

Primary myelofibrosis (PMF) is an uncommon chronic myeloproliferative disorder that is commonly associated with Janus kinase 2 (JAK-2), calreticulin (CALR), or thrombopoietin receptor (MPL) mutations. Pre-fibrotic PMF (also known as pre-PMF or early PMF) is a subtype of PMF that is defined by a lower grade of fibrosis. In this report, we present a rare case of warm autoimmune hemolytic anemia (wAIHA) associated with pre-PMF.

View Article and Find Full Text PDF

[Analysis of Genes Related to Platelet Activation in Essential Thrombocythemia Based on Transcriptomics].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

December 2024

Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.

Objective: To analyze the genes related to platelet activation in essential thrombocythemia (ET) based on transcriptome sequencing technology (RNA-seq), and to explore the potential targets related to ET thrombosis.

Methods: Blood samples from ET patients and healthy individuals were collected for RNA-seq, and differentially expressed lncRNAs, miRNAs, and mRNAs were selected to construct a lncRNA-miRNA-mRNA regulatory network. Differential mRNAs in the regulatory network were enriched and analyzed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG).

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the link between elevated vitamin B12 levels and myeloproliferative neoplasms (MPNs), which include types of blood cancers like CML, PV, MF, and ET, suggesting that higher B12 could indicate disease presence and activity.
  • Data from 467 MPN patients showed that 20% had elevated B12 levels, particularly in those with CML, with significant reductions in B12 levels observed after one year of treatment.
  • While increased B12 levels appear related to MPN activity, their effectiveness as a consistent diagnostic marker needs more research to establish reliable sensitivity, specificity, and cutoff values.
View Article and Find Full Text PDF

[Peginterferon alfa-2a monotherapy in essential thrombocythemia].

Bull Cancer

December 2024

Service de thérapie cellulaire et hématologie clinique, CHU de Clermont-Ferrand, 63100 Clermont-Ferrand, France; EA7453 CHELTER, université Clermont-Auvergne, Clermont-Ferrand, France.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!